Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Booster doses for COVID-19 vaccinations have been shown to amplify the waning immune response after primary vaccination and to enhance protection against emerging variants of concern (VoCs). Here, we aimed to assess the immunogenicity and safety of a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001) after primary vaccination with 2 doses of either VLA2001 or ChAdOx1-S (Oxford-Astra Zeneca), including the cross-neutralization capacity against the Delta and Omicron VoCs.

Source: Journal of Infection - July 3, 2023 Category: Infectious Diseases Authors: Christian Taucher, Rajeka Lazarus, Hanna Dellago, Gabriele Maurer, Petronela Weisova, Irena Corbic-Ramljak, Katrin Dubischar, Anders Lilja, Susanne Eder-Lingelbach, Romana Hochreiter, Juan Carlos Jaramillo, Helga Junker, Michael Krammer, Petra Pusic, Bene Source Type: research